How to manage lymph nodes in ovarian cancer

被引：28

作者：

Harter, Philipp ^{[1
]}

Heitz, Florian ^{[1
]}

Ataseven, Beyhan ^{[1
,2
]}

Schneider, Stephanie ^{[1
]}

Baert, Thais ^{[1
,3
]}

Prader, Sonia ^{[1
]}

du Bois, Andreas ^{[1
]}

机构：

[1] Ev Kliniken Essen Mitte, Dept Gynecol & Gynecol Oncol, Henricistr 92, D-45136 Essen, Germany

[2] Ludwig Maximilian Univ Munich, Univ Hosp, Dept Obstet & Gynecol, Munich, Germany

[3] Katholieke Univ Leuven, Dept Oncol, ImmunOvar Res Grp, Lab Tumor Immunol & Immunotherapy, Leuven, Belgium

来源：

CANCER | 2019年 / 125卷

关键词：

advanced ovarian cancer; early ovarian cancer; lymphadenectomy; Lymphadenectomy in Ovarian Neoplasms (LION); COMBINED EXPLORATORY ANALYSIS; PROGNOSTIC-SIGNIFICANCE; ADJUVANT CHEMOTHERAPY; LYMPHADENECTOMY; METASTASIS; TRIAL; CARCINOMA; PREVALENCE; TUMORS;

D O I：

10.1002/cncr.32514

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The indication for staging lymphadenectomy in patients with ovarian cancer (both early- and late-stage disease) has been a major topic of debate in the last decades. Because the Lymphadenectomy in Ovarian Neoplasms (LION) study has recently demonstrated that systematic lymphadenectomy is not beneficial to patients with advanced ovarian cancer, the discussion has become more complex for patients with early-stage ovarian cancer. Further factors, such as differences in the lymph node metastasis rates of different histologic subtypes, which were not known in the past, need to be taken into account. This review is focused on the available evidence concerning lymphadenectomy in patients with newly diagnosed ovarian cancer.

引用

页码：4573 / 4577

页数：5

共 26 条

[1] Role of lymphadenectomy in the management of grossly apparent advanced stage epithelial ovarian cancer [J].

Aletti, Giovanni D. ;

Dowdy, Sean ;

Podratz, Karl C. ;

Cliby, William A. .

AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2006, 195 (06) :1862-1868

[2] Randomized phase III trial of three versus six cycles of adjuvant carboplatin and paclitaxel in early stage epithelial ovarian carcinoma: A Gynecologic Oncology Group study [J].

Bell, Jeffrey ;

Brady, Mark F. ;

Young, Robert C. ;

Lage, Janice ;

Walker, Joan L. ;

Look, Katherine Y. ;

Rose, G. Scott ;

Spirtos, Nick M. .

GYNECOLOGIC ONCOLOGY, 2006, 102 (03) :432-439

[3] Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer [J].

Burger, Robert A. ;

Brady, Mark F. ;

Bookman, Michael A. ;

Fleming, Gini F. ;

Monk, Bradley J. ;

Huang, Helen ;

Mannel, Robert S. ;

Homesley, Howard D. ;

Fowler, Jeffrey ;

Greer, Benjamin E. ;

Boente, Matthew ;

Birrer, Michael J. ;

Liang, Sharon X. .

NEW ENGLAND JOURNAL OF MEDICINE, 2011, 365 (26) :2473-2483

[4] ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease [J].

Colombo, N. ;

Sessa, C. ;

du Bois, A. ;

Ledermann, J. ;

McCluggage, W. G. ;

McNeish, I. ;

Morice, P. ;

Pignata, S. ;

Ray-Coquard, I. ;

Vergote, I. ;

Baert, T. ;

Belaroussi, I. ;

Dashora, A. ;

Olbrecht, S. ;

Planchamp, F. ;

Querleu, D. ;

Banerjee, S. ;

Blecharz, P. ;

Bruchim, I. ;

Cibula, D. ;

Concin, N. ;

Davidson, B. ;

Devouassoux-Shisheboran, M. ;

Ferrero, A. ;

Glasspool, R. ;

Gonzalez-Martin, A. ;

Heinzelmann-Schwarz, V. ;

Joly, F. ;

Kim, J. W. ;

Kridelka, F. ;

Lorusso, D. ;

Mahner, S. ;

Mikami, M. ;

Mirza, M. R. ;

Nicum, S. ;

O'Donnell, D. M. ;

Pautier, P. ;

Rodolakis, A. ;

Sehouli, J. ;

Selcukbiricik, F. ;

Singh, N. ;

Tan, D. S. P. ;

Timmerman, D. ;

Tognon, G. ;

van der Velden, J. ;

Witteveen, P. O. ;

Zeimet, A. G. .

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2019, 29 (04) :728-760

[5] Systematic pelvic and paraaortic lymphadenectomy for advanced ovarian cancer: Prognostic significance of node metastases [J].

diRe, F ;

Baiocchi, G ;

Fontanelli, R ;

Grosso, G ;

Cobellis, L ;

Raspagliesi, F ;

diRe, E .

GYNECOLOGIC ONCOLOGY, 1996, 62 (03) :360-365

[6] A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer [J].

du Bois, A ;

Lück, HJ ;

Meier, W ;

Adams, HP ;

Möbus, V ;

Costa, S ;

Bauknecht, T ;

Richter, B ;

Warm, M ;

Schröder, W ;

Olbricht, S ;

Nitz, U ;

Jackisch, C ;

Emons, G ;

Wagner, U ;

Kuhn, W ;

Pfisterer, J .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2003, 95 (17) :1320-1330

[7] Potential Role of Lymphadenectomy in Advanced Ovarian Cancer: A Combined Exploratory Analysis of Three Prospectively Randomized Phase III Multicenter Trials [J].

du Bois, Andreas ;

Reuss, Alexander ;

Harter, Philipp ;

Pujade-Lauraine, Eric ;

Ray-Coquard, Isabelle ;

Pfisterer, Jacobus .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (10) :1733-1739

[8] Role of Surgical Outcome as Prognostic Factor in Advanced Epithelial Ovarian Cancer: A Combined Exploratory Analysis of 3 Prospectively Randomized Phase 3 Multicenter Trials By the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO) [J].

du Bois, Andreas ;

Reuss, Alexander ;

Pujade-Lauraine, Eric ;

Harter, Philipp ;

Ray-Coquard, Isabelle ;

Pfisterer, Jacobus .

CANCER, 2009, 115 (06) :1234-1244

[9] GEICO (Spanish Group for Investigation on Ovarian Cancer) treatment guidelines in ovarian cancer 2012 [J].

Gonzalez Martin, A. ;

Redondo, A. ;

Jurado, M. ;

De Juan, A. ;

Romero, I. ;

Bover, I. ;

Del Campo, J. M. ;

Cervantes, A. ;

Garcia, Y. ;

Lopez-Guerrero, J. A. ;

Mendiola, C. ;

Palacios, J. ;

Rubio, M. J. ;

Poveda Velasco, A. .

CLINICAL & TRANSLATIONAL ONCOLOGY, 2013, 15 (07) :509-525

[10]

Gouy S, 2017, GYNECOL ONCOL REP, V22, P21, DOI 10.1016/j.gore.2017.08.006

← 1 2 3 →